Bellerophon Therapeutics, Inc. (BLPH)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
As of 12:48PM EDT. Market open.
| Previous Close | 0.0563 |
| Open | 0.0563 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1400 |
| Day's Range | 0.0563 - 0.0563 |
| 52 Week Range | 0.0290 - 11.1500 |
| Volume | |
| Avg. Volume | 26,053 |
| Market Cap | 688,695 |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeu
© 2024 Yahoo. All rights reserved.